Eribulin promotes proliferation of CD8+ T cells and potentiates T cell-mediated anti-tumor activity against triple-negative breast cancer cells

ConclusionsEribulin promoted CD8+T cell proliferation, repressed effectorT cell differentiation, and harnessedT cell-mediated anti-tumor effects. These mechanisms may be one of the cues that eribulin can improve the immunological status of tumor-bearing hosts.

http://link.springer.com/10.1007/s10549-023-07111-x

Source: Breast Cancer Research and Treatment - January 1, 2024 Category: Cancer & Oncology Source Type: research